Vaxcyte Stock - insider equity awards follow annual meeting
17.06.2026 - 16:57:43 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 14:55 UTC. Details in the imprint.
Vaxcyte (US92242T1016) has reported new equity awards for two of its directors in fresh Form 4 disclosures. The filings come just days after the company’s June 15 annual meeting of stockholders, according to the SEC information summarized by Stock Titan.
All news and key data on Vaxcyte stock
Stay on top of Vaxcyte’s pipeline milestones, board decisions and stock performance with our continuously updated topic page.
What the new filings show
According to a summary of the latest Form 4, director Carlos V. Paya received 2,265 restricted stock units and 11,389 stock options with a $49.56 exercise price, granted as director compensation. The options expire on June 15, 2036 and vest monthly through June 15, 2027.
A separate Form 4 summary indicates director John Furey received an identical package: 2,265 RSUs and 11,389 options also struck at $49.56 per share, expiring on June 15, 2036. His RSUs fully vest on the earlier of June 15, 2027 or the day before the next annual meeting.
Board decisions and operations backdrop
The equity awards follow Vaxcyte’s annual meeting on June 15, where shareholders re-elected three Class III directors and approved governance-related proposals, according to a recent meeting update. That aligns the compensation grants with the start of a new board term.
Operationally, Vaxcyte remains focused on advancing its pneumococcal and other conjugate-vaccine candidates, including the clinic-ready VAX-24 program and earlier-stage assets, as outlined in recent company presentations. Cash burn and trial timelines stay central to the investment case in the coming quarters.
How the company makes money
Vaxcyte is a clinical-stage vaccine developer aiming to commercialize next-generation conjugate vaccines such as VAX-24 for invasive pneumococcal disease, with longer-term optionality in programs like VAX-A1 targeting Group A Streptococcus. Revenue today comes mainly from collaboration and financing activities rather than product sales.
Where the stock trades today
The shares of Vaxcyte (US92242T1016) trade on Nasdaq at $49.31 as of 06/17/2026, 14:30 UTC.
Key facts on Vaxcyte stock
- Company: Vaxcyte, Inc.
- ISIN: US92242T1016
- WKN: A2P0LE
- Ticker: PCVX
- Venue: Nasdaq
- Price (as of 06/17/2026, 14:30 UTC): 49.31 USD
- Market cap: 5,10?0,000,000 USD (as of 06/17/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: not a member of the S&P 500 or Nasdaq-100
- Next earnings date: estimated 08/05/2026, not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
